SCHEMBL7053042

SCHEMBL7053042

CCCC(C(=O)OCC)C(OCC)[PH](=O)CSc1ccc2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRNP P04156 9/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 2/20 0.52
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPT P10636 4/20 0.43
RXFP1 Q9HBX9 6/20 0.41
KDM4E B2RXH2 2/20 0.41
NPSR1 Q6W5P4 4/20 0.40
MAPK10 P53779 2/20 0.40
THRB P10828 1/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
PTBP1 P26599 1/20 0.38
HPGD P15428 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8764768 0.89 PRNP (0.51) PRNPKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL7050341 0.82 CYP3A4 (0.39) ALDH1A1MAPTKDM4ELMNANPC1
SCHEMBL7052159 0.81 POLB (0.40) KMT2AMEN1ALDH1A1L3MBTL1MAPT
SCHEMBL7244423 0.80 ALDH1A1 (0.36) KMT2AMEN1ALDH1A1MAPTKDM4E
SCHEMBL7049818 0.78 PRNP (0.48) PRNPKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL8764852 0.72 PRNP (0.57) PRNPKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL9067056 0.71 PRNP (0.53) PRNPKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL7049726 0.71 PRNP (0.50) PRNPKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL8764856 0.69 PRNP (0.53) PRNPKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL7244226 0.69 PRNP (0.53) PRNPKMT2AMEN1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 PRNP 327/4885KMT2A 4072/4885MEN1 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.